about

Dr. Gujrathi joins Receptos from Bristol-Myers Squibb where she was Vice President of the Global Clinical Development Group in Immunology. In that role, she was responsible for late stage clinical development and global regulatory submissions for Orencia^® (both intravenous and subcutaneous formulations), Nulojix^® in solid organ transplant, and other clinical immunology assets being developed in rheumatoid arthritis, systemic lupus erythematosus, inflammatory bowel disease, solid organ transplant, scleroderma, and other immunology indications. Dr. Gujrathi was instrumental in preparing and gaining regulatory approvals in the US, EU, and other countries for Orencia® IV and SC sBLA applications in RA and JIA, and for Nulojix^® in kidney transplant recipients which included a positive FDA advisory committee hearing. In addition, she provided strategic direction for the Immunoscience franchise at BMS for both the discovery and early development internal pipeline as well as external business development opportunities where she was involved in licensing agreements and/or acquisitions of several immunology and fibrosis compounds both in the discovery and clinical stages of development. Prior to joining BMS, Dr. Gujrathi was a management consultant at McKinsey & Company in the healthcare practice where she provided strategic advice on a variety of projects in the healthcare and pharmaceutical industry. She then spent several years at Genentech where she held roles of increasing responsibility in the Immunology, Tissue Growth and Repair clinical development group. She worked on a number of clinical programs in the immunology area including Xolair^® in IgE-mediated asthma, Rituximab^® and ocrelizumab in multiple autoimmune disorders, Raptiva^®, and other early development compounds where she was involved in filing INDs and initiating early clinical trials. At Genentech, she also held the role of Avastin^® Franchise Team Leader helping to develop strategies in multiple oncology indications. Sheila received her B.S. with highest distinction in Biomedical Engineering and M.D. from Northwestern University in their accelerated Honors Program in Medical Education. She completed her Internal Medicine Internship and Residency at Brigham and Women's Hospital, Harvard Medical School and is board certified in internal medicine. She received additional training at UCSF and Stanford in their Allergy and Immunology Fellowship Program.

Ms. Mineo comes to Receptos with over 20 years experience in the biotechnology industry. In her most recent position, Ms. Mineo was Senior Director of Business Development for Neurocrine Biosciences, where she spent 12 years specializing in both world-wide and regional development and commercialization collaborations for Neurocrine's GPCR directed therapeutic candidates, predominantly in the areas of CNS, endocrinology, and metabolism. She also led technical due diligence and negotiations for several successfully in-licensed candidates in both preclinical and clinical development. Ms. Mineo established multiple technology collaborations for Neurocrine to support the acceleration of drug discovery efforts in the GPCR field, including in the areas of receptor screening, computational chemistry, and GPRC targeted screening libraries. Prior to Neurocrine, Ms. Mineo served in various capacities in research, marketing, and business development for such companies as Amgen, DNAX Research Institute, Schering Plough, and Baxter Biotech. She began her career in 1987 with Amgen as a member of a cellular biology team investigating the therapeutic role of Neupogen. Ms. Mineo holds a B.S. in zoology from the University of California, Davis and received her M.B.A. from Duke University's Fuqua School of Business.

Dr. Peach comes to Receptos with 19 years of pharmaceutical and biotechnology company experience, successfully discovering and developing drugs in the areas of autoimmunity/inflammation and oncology. In his most recent position, Dr. Peach was Senior Director of Oncology Discovery at Biogen Idec where he had responsibility for several bicoastal research programs, two of which have entered clinical trials. Dr. Peach was also responsible for leading technical due diligence efforts that lead to a 3-compound co-development deal with Protein Design Labs, acquisition of Conforma Therapeutics, and a venture investment in GlobeImmune including a subsequent appointment to their Scientific Advisory Board. Prior to joining Biogen Idec, Dr. Peach held several research positions with increasing responsibility at Bristol-Myers Squibb. During that time he played an integral role in the research and development of Orencia^®, now registered for the treatment of rheumatoid arthritis. He also led a program that discovered and developed belatacept (Nulojix^®), a drug recently approved for the treatment of solid organ transplant rejection. Dr. Peach has authored over 60 peer-reviewed publications and 11 patents. He received his B.S. and M.S. (1st class honors) from the University of Canterbury and a Ph.D. in Biochemistry from the University of Otago, New Zealand.

Mr. Schmidt joins Receptos bringing to bear extensive finance and operations experience. He was formerly Senior Director of Finance and Operations at Conforma Therapeutics until the successful acquisition by Biogen Idec where he assisted in the transition and integration of the companies. Prior to that, Mr. Schmidt served in various financial and operational roles including Chief Financial Officer for Kent SeaTech Corporation, Controller for Medical Imaging Centers of America, Inc and MCA, Inc. / MCA Concerts, Inc., and Manager of Accounting - Retirement Inns of America, Inc. He has managed the finances, human resources, information technology and facilities of companies from start-up to maturity. He started his career with Coopers & Lybrand and received his B.S. in Accounting and Corporate Finance from Drake University in Des Moines, Iowa.